myd88 mice (Jackson Laboratory)
Structured Review
Myd88 Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/myd88 mice/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "MyD88 deficiency modestly attenuates disease in a Leigh syndrome mouse model while enrofloxacin accelerates disease"
Article Title: MyD88 deficiency modestly attenuates disease in a Leigh syndrome mouse model while enrofloxacin accelerates disease
Journal: bioRxiv
doi: 10.64898/2026.05.13.724988
Figure Legend Snippet:
Techniques Used: Produced
Figure Legend Snippet:
Techniques Used:
Figure Legend Snippet: A) NanoString-based analysis of Toll-like receptor ( Tlr ) and MyD88 expression in the brainstem of 45-day old control and Ndufs4 (-/-) mice (see Methods ). Black – Ndufs4 (Ctl), Red – Ndufs4 (-/-) (see Methods ). p-values reflect multiple testing corrected (Holm-Šídák method) pairwise t-tests. *p<0.05, ns and those not shown – not significant. B ) Taqman probe-based qPCR analysis of Tlr7, Tlr9 , and MyD88 expression in 50-day old control and Ndufs4 (-/-) mouse brainstem samples. Normalized to actin, included in each reaction. Black – Ndufs4 (Ctl), Red – Ndufs4 (-/-) (see Methods ). Relative expression calculated using relative standard curve approach. *p<0.05, ns – not significant, by Holm-Šídák method multiple-testing corrected pairwise t-tests with Welch’s correction (no assumption regarding standard deviation).
Techniques Used: Expressing, Control, Standard Deviation
Figure Legend Snippet: A) Impact of enrofloxacin and MyD88 disruption on overall weight trajectory in Nduf4 (-/-) mice (see Results, , ). Replicates (n’s) as indicated. B) Maximum weights of individual animals in A). Replicates (n’s) as indicated in A). ANOVA and pairwise comparisons were not statistically significant. C) Impact of enrofloxacin and MyD88 disruption on the onset of cachexia (weight loss) in Nduf4 (-/-) mice. No curves significantly different by pairwise log-rank comparison. Replicates (n’s) as indicated.
Techniques Used: Disruption, Comparison
Figure Legend Snippet: A) Impact of enrofloxacin and MyD88 disruption on ataxia onset in Nduf4 (-/-) mice. n’s as indicated. The dot (MyD88(-/-) cohort) represents an animal which died prior to presenting with ataxia. P-value shown indicates pairwise log-rank test comparisons between curves indicated - **p<0.005. B) Impact of enrofloxacin and MyD88 disruption on the onset of clasping in Nduf4 (-/-) mice. n’s as indicated. The dot (MyD88(-/-) cohort) represents an animal which died prior to presenting with clasping. P-value shown indicates pairwise log-rank test comparisons between curves indicated - **p<0.005.
Techniques Used: Disruption
Figure Legend Snippet: A) Impact of enrofloxacin and MyD88 disruption on survival in Nduf4 (-/-) mice (see Methods , introduction). P-values shown indicate pairwise log-rank test comparisons between curves indicated - **p=0.0087, *p<0.013. n’s as indicated. B) Cause of death in mice from A). FDIC – found dead in cage, cause of death unknown. C) Summary of findings. Enrofloxacin treatment modestly accelerates disease progression in the Ndufs4 (-/-) model, while loss of MyD88 modestly slows disease progression and extends survival.
Techniques Used: Disruption, Biomarker Discovery


